Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Surgical Oncology
Published in: Indian Journal of Surgical Oncology 1/2023

01-09-2022 | Breast Cancer | Review Article

Ki 67: a Promising Prognostic Marker in Early Breast Cancer—a Review Article

Authors: Dhanya Mary Louis, Lakshmi Malavika Nair, Archana George Vallonthaiel, M. P. Narmadha, D. K. Vijaykumar

Published in: Indian Journal of Surgical Oncology | Issue 1/2023

Login to get access

Abstract

Ki67 index is considered to be a reliable indicator of the proliferative activity of breast cancer. Additionally, the Ki67 proliferative marker may play a role in assessing response to systemic therapeutic strategies and can act as a prognostic biomarker. But its limited reproducibility which stems from a lack of standardization of procedures, inter-observer variability, and preanalytical and analytical variabilities all have hampered the use of the Ki67 index in clinical practice. Currently, clinical trials have been evaluating Ki67 as a predictive marker for needing adjuvant chemotherapy in luminal early breast cancer patients receiving neoadjuvant endocrine therapy. But the inconsistencies existing in the estimation of the Ki67 index limit the utility of Ki67 in standard clinical practice. The purpose of this review is to evaluate the benefits and drawbacks of utilizing Ki-67 in early-stage breast cancer to prognosticate the disease and predict the risk of recurrence.
Literature
1.
2.
Dai X, Li T, Bai Z et al (2015) Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res 5:2929–2943PubMedPubMedCentral
3.
4.
Onitilo AA, Engel JM, Greenlee RT et al (2009) Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7:4–13CrossRefPubMedPubMedCentral
5.
Liang Q, Ma D, Gao RF et al (2020) Effect of Ki-67 expression levels and histological grade on breast cancer early relapse in patients with different immunohistochemical-based subtypes. Sci Rep 10:7648CrossRefPubMedPubMedCentral
6.
Kunheri B, Raj RV, Vijaykumar DK et al (2020) Impact of St. Gallen surrogate classification for intrinsic breast cancer sub-types on disease features, recurrence, and survival in south Indian patients. Indian J Cancer 57:49–54CrossRefPubMed
7.
Vijaykumar DK, Arun S et al (2019) Breast cancer care in south India: is practice concordant with national guidelines? J Glob Oncol 5:1–7PubMed
8.
Li LT, Jiang G, Chen Q, Zheng JN (2014) Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep 11:1566–1572CrossRefPubMed
9.
Dowsett M, Nielsen TO, A’Hern R et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103:1656–1664CrossRefPubMedPubMedCentral
10.
11.
12.
13.
Korde LA, Somerfield MR, Carey LA et al (2021) Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol 39:1485–1505CrossRefPubMedPubMedCentral
14.
Smith I, Robertson J, Kilburn L et al (2020) Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomized, phase 3 trial. Lancet Oncol 21:1443–1454CrossRefPubMedPubMedCentral
15.
Nielsen TO, Leung SCY, Rimm DL et al (2021) Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. J Nat Cancer Inst 113:808–819CrossRefPubMed
16.
17.
Ellis MJ, Suman VJ, Hoog J et al (2017) Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol 35:1061–1069CrossRefPubMedPubMedCentral
18.
Suman VJ, Ellis MJ, Ma CX (2015) The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancer. Chin Clin Oncol 4:34PubMedPubMedCentral
19.
Dowsett M, Smith IE, Ebbs SR et al (2005) Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 11:951s–8s
20.
Vaz-Luis I, O’Neill A, Sepucha K et al (2017) Survival benefit needed to undergo chemotherapy: patient and physician preferences. Cancer 123:2821–2828CrossRefPubMed
21.
22.
Choudhari AS, Mandave PC, Deshpande M et al (2020) Phytochemicals in cancer treatment: from preclinical studies to clinical practice. Front Pharmacol 10:1614CrossRefPubMedPubMedCentral
23.
Guerrero-Zotano AL, Arteaga CL (2017) Neoadjuvant trials in ER+ breast cancer: a tool for acceleration of drug development and discovery. Cancer Discov 7:561–574CrossRefPubMedPubMedCentral
24.
Al-Mahmood S, Sapiezynski J, Garbuzenko OB et al (2018) Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res 8:1483–1507CrossRefPubMedPubMedCentral
25.
26.
Buus R, Sestak I, Kronenwett R et al (2021) Molecular drivers of oncotype DX, prosigna, EndoPredict, and the breast cancer index: A TransATAC study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 39:126–135CrossRefPubMed
27.
Chalkidou A, Landau DB, Odell EW et al (2012) Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: a systematic review and meta-analysis. Eur J Cancer 48:3499–3513CrossRefPubMed
28.
29.
Rui G, Li M, Xiomei B et al (2021) Scoring method for immunohistochemical staining on Ki67. Appl Immunohistochem Mol Morphol 29:e20–e28
30.
Khoury T (2018) Delay to formalin fixation (cold ischemia time) effect on breast cancer molecules. Am J Clin Pathol 149:275–292CrossRefPubMed
31.
Polley MY, Leung SC, McShane LM et al (2013) International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (2013). An international Ki67 reproducibility study. J Natl Cancer Inst 105:1897–1906CrossRefPubMedPubMedCentral
32.
Metadata
Title
Ki 67: a Promising Prognostic Marker in Early Breast Cancer—a Review Article
Authors
Dhanya Mary Louis
Lakshmi Malavika Nair
Archana George Vallonthaiel
M. P. Narmadha
D. K. Vijaykumar
Publication date
01-09-2022
Publisher
Springer India
Published in
Indian Journal of Surgical Oncology / Issue 1/2023
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-022-01631-6

Other articles of this Issue 1/2023

Indian Journal of Surgical Oncology 1/2023 Go to the issue

Original Article

Surgical and Survival Outcomes of Operable Gastric Cancer—Experience from a Tertiary Care Center in South India

Guest Editorial

How to Develop and Implement Computerized Comprehensive Clinical Database in Oncology—the Way Forward

Letter to the Editor

Cellular Fibroma Ovary with Minor Sex Cord Elements Associated with Endometrial Adenocarcinoma: a Rare Entity

Point of Technique

Why Should We Avoid Excisional Biopsy of Breast Lump? ASOMA Guide for Managing a Discrete Breast Lump 

Original Article

Povidone Iodine Sclerotherapy for the Treatment of Persistent Seromas after Breast Cancer Surgery

Original Article

Cancer Stem Cell Markers — CD133 and CD44 — in Paediatric Solid Tumours: A Study of Immunophenotypic Expression and Correlation with Clinicopathological Parameters